查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1312438

血栓治療的全球市場的預測(～2030年)

Thrombus Treatment Market Forecast to 2030
出版日期: | 出版商: Market Research Future | 英文 128 Pages | 訂單完成後即時交付

價格

全球血栓治療的市場規模在預測期間內將以年複合成長率6.84％的速度成長。

本報告提供全球血栓治療市場相關調查分析，提供市場動態，地區和市場區隔的分析，企業簡介等資訊。

目錄

第1章 摘要整理

第2章 市場簡介

第3章 調查手法

第4章 市場動態

  • 概要
  • 促進因素
    • 外傷的發生增加
    • 久坐生活方式的普及
  • 阻礙因素
    • 血栓症藥相關的風險
  • 機會
    • 新產品的認證與發售

第5章 市場要素的分析

  • 價值鏈分析
    • 研究開發
    • 製造
    • 流通·銷售
    • 銷售後的監測
  • 波特的五力分析
  • COVID-19對全球血栓治療市場的影響
    • 供應鏈的影響
    • 生產的影響
    • 供需缺口分析
    • 價格設定的影響
  • 肺動脈栓塞的治療數量

第6章 全球血栓治療市場:各類型

  • 概要
  • 心房血栓
  • 靜脈血栓

第7章 全球血栓治療市場:不同治療

  • 概要
  • 藥物治療
  • 手術
  • 其他

第8章 全球血栓治療市場:各地區

  • 概要
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第9章 競爭情形

  • 概要
  • 競爭基準
  • 全球血栓治療市場上主要成長策略
  • 全球血栓治療市場上開發數的主要企業
  • 主要的發展的分析
  • 主要的發展與成長策略
    • 產品的認證/產品的銷售
    • 夥伴關係/聯盟
  • 主要企業的財務矩陣
    • 銷售額(2021年)
    • 研究開發(2021年)

第10章 企業簡介

  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • SANOFI
  • PFIZER INC.
  • BAYER AG
  • ANGIODYNAMICS.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BRISTOL-MYERS SQUIBB COMPANY
  • ASPEN HOLDINGS
  • JOHNSON & JOHNSON SERVICES, INC.
  • DAIICHI SANKYO COMPANY, LIMITED

第11章 附錄

Product Code: MRFR/HC/9934-CR

Market Overview

The thrombus treatment market is projected to enroll a solid CAGR of 6.84% during the conjecture time frame. The elements impacting the market development are the rising rate of injury cases and the rising reception of a stationary way of life supporting the market development.

Injury is viewed as one of the most widely recognized reasons for the arrangement of thrombus in the lower limits. At the point when any veins get harmed, the encompassing blood thickens and frames a coagulation. Subsequently, vein harm because of injury can cause the development of a thrombus. The expanded number of injury cases, particularly street mishaps has prompted an expansion popular of thrombus treatment. As per the WHO in June2018, around 1.3 million individuals lose their lives because of street mishaps universally. Moreover, there were 178 million new break cases enlisted in 2019 worldwide which had expanded by 33.4% beginning around 1990. The absolute pervasiveness of intense and long-haul break side effects had reached 455 million of every 2910 with an increment of 67.5% starting around 1990. The break is one more typical reason for apoplexy. Consequently, the rising occurrence of injury cases is driving market interest in Thrombus Treatment.

Market Segmentation

Atrial and venous thrombus are the two market segments for thrombus treatment, respectively. Right atrial thrombus and left atrial thrombus were formed from the atrial thrombus.

Data on the thrombus treatment market has been divided into treatment categories such as medicinal therapy, surgery, and others. Thrombolytics, antiplatelets, and anticoagulants make up the medical therapy component.

Regional Analysis

North America held the biggest market share and contributed USD 16.19 billion of every 2021 attributable to created medical care foundation, research awards for delivering protected and powerful thrombus treatment, and the developing matured and large populace in the region.

Europe's thrombus treatment market represents the second-biggest market share attributable to the developing examination and treatment of profound vein apoplexy and developing mindfulness with respect to thrombus difficulties are the central point driving the market development in Europe. For example, as per the article distributed in Public Community for Biotechnology Data (NCBI), profound vein apoplexy (DVT) is a medical services trouble in Europe.

The Asia-Pacific thrombus treatment market is supposed to develop at a critical share from2018 to 2030. Attributable to the presence of an enhanced patient pool, the rising pervasiveness of profound vein apoplexy, and expanding mindfulness about the treatment and utilization of medications to treat different apoplexy occasions in nations, for example, China and India are probably going to support the market in the Asia-Pacific region. In addition, China market of thrombus treatment held the biggest market share, and the India market of thrombus treatment is the quickest developing market in the Asia-Pacific region.

Major Players

Key companies in the Thrombus Treatment Market includes Teva Pharmaceutical Industries Ltd. (Israel), AngioDynamics Inc. (US), Bristol-Myers Squibb Company (US), Pfizer Inc. (US), Johnson & Johnson Services Inc. (US), Sanofi S.A. (France), Daiichi Sankyo Company, Limited (Tokyo), Boehringer Ingelheim International GmbH (Germany), Aspen Pharmacare Holdings Limited (US), and Bayer AG (Germany).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 OVERVIEW

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE
  • 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING INCIDENCE OF TRAUMA CASES
    • 4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLE
  • 4.3 RESTRAINTS
    • 4.3.1 RISKS ASSOCIATED WITH THROMBOSIS DRUGS
  • 4.4 OPPORTUNITIES
    • 4.4.1 NEW PRODUCT APPROVALS AND LAUNCHES

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION AND SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE GLOBAL THROMBUS TREATMENT MARKET
    • 5.3.1 IMPACT ON SUPPLY CHAIN
    • 5.3.2 IMPACT ON PRODUCTION
    • 5.3.3 DEMAND-SUPPLY GAP ANALYSIS
    • 5.3.4 IMPACT ON PRICING
  • 5.4 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM

6 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE

  • 6.1 OVERVIEW
  • 6.2 ATRIAL THROMBUS
  • 6.3 VENOUS THROMBUS

7 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT

  • 7.1 OVERVIEW
  • 7.2 MEDICAL THERAPY
  • 7.3 SURGERY
  • 7.4 OTHERS

8 GLOBAL THROMBUS TREATMENT MARKET, BY REGION

  • 8.1 OVERVIEW
    • 8.1.1 NORTH AMERICA
      • 8.1.1.1 US
      • 8.1.1.2 CANADA
    • 8.1.2 EUROPE
      • 8.1.2.1 GERMANY
      • 8.1.2.2 UK
      • 8.1.2.3 FRANCE
      • 8.1.2.4 ITALY
      • 8.1.2.5 SPAIN
      • 8.1.2.6 REST OF EUROPE
    • 8.1.3 ASIA-PACIFIC
      • 8.1.3.1 JAPAN
      • 8.1.3.2 CHINA
      • 8.1.3.3 INDIA
      • 8.1.3.4 AUSTRALIA
      • 8.1.3.5 SOUTH KOREA
      • 8.1.3.6 REST OF ASIA-PACIFIC
    • 8.1.4 REST OF THE WORLD
      • 8.1.4.1 MIDDLE EAST
      • 8.1.4.2 AFRICA
      • 8.1.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 COMPETITIVE BENCHMARKING
  • 9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL THROMBUS TREATMENT MARKET
  • 9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL THROMBUS TREATMENT MARKET
  • 9.5 KEY DEVELOPMENT ANALYSIS
  • 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 9.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES
    • 9.6.2 PARTNERSHIP/COLLABORATION
  • 9.7 MAJOR PLAYERS FINANCIAL MATRIX
    • 9.7.1 SALES (USD MILLION), 2021
    • 9.7.2 R&D (USD MILLION), 2021

10 COMPANY PROFILES

  • 10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.1.1 COMPANY OVERVIEW
    • 10.1.2 FINANCIAL ANALYSIS
    • 10.1.3 PRODUCTS OFFERED
    • 10.1.4 KEY DEVELOPMENTS
    • 10.1.5 SWOT ANALYSIS
    • 10.1.6 KEY STRATEGIES
  • 10.2 SANOFI
    • 10.2.1 COMPANY OVERVIEW
    • 10.2.2 FINANCIAL OVERVIEW
    • 10.2.3 PRODUCTS OFFERED
    • 10.2.4 KEY DEVELOPMENTS
    • 10.2.5 SWOT ANALYSIS
    • 10.2.6 KEY STRATEGIES
  • 10.3 PFIZER INC.
    • 10.3.1 COMPANY OVERVIEW
    • 10.3.2 FINANCIAL OVERVIEW
    • 10.3.3 PRODUCTS OFFERED
    • 10.3.4 KEY DEVELOPMENTS
    • 10.3.5 SWOT ANALYSIS
    • 10.3.6 KEY STRATEGIES
  • 10.4 BAYER AG
    • 10.4.1 COMPANY OVERVIEW
    • 10.4.2 FINANCIAL OVERVIEW
    • 10.4.3 PRODUCTS OFFERED
    • 10.4.4 KEY DEVELOPMENTS
    • 10.4.5 KEY STRATEGIES
  • 10.5 ANGIODYNAMICS.
    • 10.5.1 COMPANY OVERVIEW
    • 10.5.2 FINANCIAL OVERVIEW
    • 10.5.3 PRODUCTS OFFERED
    • 10.5.4 KEY DEVELOPMENTS
    • 10.5.5 KEY STRATEGIES
  • 10.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 10.6.1 COMPANY OVERVIEW
    • 10.6.2 FINANCIAL OVERVIEW
    • 10.6.3 PRODUCTS OFFERED
    • 10.6.4 KEY DEVELOPMENTS
    • 10.6.5 SWOT ANALYSIS
    • 10.6.6 KEY STRATEGIES
  • 10.7 BRISTOL-MYERS SQUIBB COMPANY
    • 10.7.1 COMPANY OVERVIEW
    • 10.7.2 FINANCIAL OVERVIEW
    • 10.7.3 PRODUCTS OFFERED
    • 10.7.4 KEY DEVELOPMENTS
    • 10.7.5 KEY STRATEGIES
  • 10.8 ASPEN HOLDINGS
    • 10.8.1 COMPANY OVERVIEW
    • 10.8.2 FINANCIAL OVERVIEW
    • 10.8.3 PRODUCTS OFFERED
    • 10.8.4 KEY DEVELOPMENTS
    • 10.8.5 KEY STRATEGIES
  • 10.9 JOHNSON & JOHNSON SERVICES, INC.
    • 10.9.1 COMPANY OVERVIEW
    • 10.9.2 FINANCIAL OVERVIEW
    • 10.9.3 PRODUCTS OFFERED
    • 10.9.4 KEY DEVELOPMENTS
    • 10.9.5 SWOT ANALYSIS
    • 10.9.6 KEY STRATEGIES
  • 10.10 DAIICHI SANKYO COMPANY, LIMITED
    • 10.10.1 COMPANY OVERVIEW
    • 10.10.2 FINANCIAL OVERVIEW
    • 10.10.3 PRODUCTS OFFERED
    • 10.10.4 KEY DEVELOPMENTS
    • 10.10.5 KEY STRATEGIES

11 APPENDIX

  • 11.1 REFERENCES
  • 11.2 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM, BY REGION (2021)
  • TABLE 4 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5 GLOBAL THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6 GLOBAL THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 7 GLOBAL THROMBUS TREATMENT MARKET, FOR RIGHT ATRIAL THROMBUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8 GLOBAL THROMBUS TREATMENT MARKET, FOR LEFT ATRIAL THROMBUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9 GLOBAL THROMBUS TREATMENT MARKET, FOR VENOUS THROMBUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11 GLOBAL THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12 GLOBAL THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13 GLOBAL THROMBUS TREATMENT MARKET, FOR ANTIPLATELETS BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14 GLOBAL THROMBUS TREATMENT MARKET, FOR ANTICOAGULANTS BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15 GLOBAL THROMBUS TREATMENT MARKET, FOR THROMBOLYTICS BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16 GLOBAL THROMBUS TREATMENT MARKET, FOR SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17 GLOBAL THROMBUS TREATMENT MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18 GLOBAL: THROMBUS TREATMENT MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21 NORTH AMERICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
  • TABLE 22 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23 NORTH AMERICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24 US: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25 US: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26 US: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030
  • TABLE 27 US: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28 CANADA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29 CANADA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
  • TABLE 30 CANADA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31 CANADA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32 EUROPE: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33 EUROPE: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34 EUROPE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35 EUROPE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36 EUROPE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37 GERMANY: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38 GERMANY: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39 GERMANY: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40 GERMANY: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41 UK: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42 UK: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43 UK: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44 UK: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45 FRANCE: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46 FRANCE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47 FRANCE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48 FRANCE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49 ITALY: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50 ITALY: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51 ITALY: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52 ITALY: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53 SPAIN: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54 SPAIN: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55 SPAIN: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56 SPAIN: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57 REST OF EUROPE: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58 REST OF EUROPE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59 REST OF EUROPE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60 REST OF EUROPE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
  • TABLE 64 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65 ASIA-PACIFIC: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66 JAPAN: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67 JAPAN: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68 JAPAN: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69 JAPAN: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70 CHINA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71 CHINA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72 CHINA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73 CHINA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74 INDIA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75 INDIA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76 INDIA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77 INDIA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78 AUSTRALIA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79 AUSTRALIA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80 AUSTRALIA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81 AUSTRALIA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82 SOUTH KOREA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83 SOUTH KOREA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84 SOUTH KOREA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85 SOUTH KOREA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92 REST OF THE WORLD: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
  • TABLE 93 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94 REST OF THE WORLD: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95 MIDDLE EAST: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96 MIDDLE EAST: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
  • TABLE 97 MIDDLE EAST: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98 MIDDLE EAST: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99 AFRICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100 AFRICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
  • TABLE 101 AFRICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102 AFRICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103 LATIN AMERICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
  • TABLE 105 LATIN AMERICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106 LATIN AMERICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107 MAJOR PLAYERS IN THE GLOBAL THROMBUS TREATMENT MARKET
  • TABLE 108 MOST ACTIVE PLAYERS IN THE GLOBAL THROMBUS TREATMENT MARKET
  • TABLE 109 PRODUCT APPROVALS/PRODUCT LAUNCHES
  • TABLE 110 PARTNERSHIP/COLLABORATION
  • TABLE 111 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 112 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
  • TABLE 113 SANOFI: PRODUCTS OFFERED
  • TABLE 114 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 115 BAYER AG: PRODUCTS OFFERED
  • TABLE 116 BAYER AG: KEY DEVELOPMENTS
  • TABLE 117 ANGIODYNAMICS.: PRODUCTS OFFERED
  • TABLE 118 ANGIODYNAMICS.: KEY DEVELOPMENTS
  • TABLE 119 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
  • TABLE 120 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
  • TABLE 121 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS
  • TABLE 122 ASPEN HOLDINGS: PRODUCTS OFFERED
  • TABLE 123 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 124 JOHNSON & JOHNSON SERVICES INC.: KEY DEVELOPMENTS
  • TABLE 125 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL THROMBUS TREATMENT MARKET
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: GLOBAL THROMBUS TREATMENT MARKET
  • FIGURE 5 DRIVERS: IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT: IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL THROMBUS TREATMENT MARKET
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL THROMBUS TREATMENT MARKET
  • FIGURE 9 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE, 2021 & 2030 (USD MILLION)
  • FIGURE 10 GLOBAL THROMBUS TREATMENT MARKET SHARE (%), BY TYPE, 2021
  • FIGURE 11 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT, 2021 & 2030 (USD MILLION)
  • FIGURE 12 GLOBAL THROMBUS TREATMENT MARKET SHARE (%), BY TREATMENT, 2021
  • FIGURE 13 GLOBAL: THROMBUS TREATMENT MARKET, BY REGION 2021 & 2030 (USD MILLION)
  • FIGURE 14 GLOBAL: THROMBUS TREATMENT MARKET SHARE (%), BY REGION 2021
  • FIGURE 15 NORTH AMERICA: THROMBUS TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
  • FIGURE 16 NORTH AMERICA: THROMBUS TREATMENT MARKET SHARE, BY COUNTRY, 2021
  • FIGURE 17 EUROPE: THROMBUS TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
  • FIGURE 18 ASIA-PACIFIC: THROMBUS TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
  • FIGURE 19 ASIA-PACIFIC: THROMBUS TREATMENT MARKET SHARE, BY COUNTRY, 2021
  • FIGURE 20 REST OF THE WORLD: THROMBUS TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
  • FIGURE 21 REST OF THE WORLD: THROMBUS TREATMENT MARKET SHARE, BY COUNTRY, 2021
  • FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 23 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL THROMBUS TREATMENT MARKET
  • FIGURE 24 GLOBAL THROMBUS TREATMENT MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 25 SALES, 2021
  • FIGURE 26 R&D, 2021
  • FIGURE 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
  • FIGURE 29 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 SANOFI.: SWOT ANALYSIS
  • FIGURE 31 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 32 PFIZER INC: SWOT ANALYSIS
  • FIGURE 33 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 34 ANGIODYNAMICS.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 35 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 36 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS
  • FIGURE 37 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 38 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW
  • FIGURE 40 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS
  • FIGURE 41 DAIICHI SANKYO COMPANY, LIMITED: FINANCIAL OVERVIEW